The effect of finasteride in men with benign prostatic hyperplasia

Birkhoff, 1983, Natural history of benign prostatic hypertrophy, 5 Rotkin, 1983, Origins, distribution and risk of benign prostatic hypertrophy, 10 Glynn, 1985, The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study, Am J Epidemiol, 121, 78 Roos, 1989, Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia, N Engl J Med, 320, 1120, 10.1056/NEJM198904273201705 Bosch, 1998, Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters, J Urol, 141, 68, 10.1016/S0022-5347(17)40591-X Peters, 1987, The effect of nafareline acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia, N Engl J Med, 317, 599, 10.1056/NEJM198709033171004 Imperato-McGinley, 1974, Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism, Science, 186, 1213, 10.1126/science.186.4170.1213 Walsh, 1974, Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineosrotal hypospadias, N Engl J Med, 291, 944, 10.1056/NEJM197410312911806 Ramusson, 1987, Biochemistry and pharmacology of 5α-reductase inhibitors, 308 Gormley, 1991, The role of 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia, Vol. 5, 436 Rittmaster, 1989, Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men, J Androl, 10, 259, 10.1002/j.1939-4640.1989.tb00097.x Gormley, 1990, Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers, J Clin Endocrinol Metab, 70, 1136, 10.1210/jcem-70-4-1136 Stoner, 1992, The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia, J Urol, 147, 1298, 10.1016/S0022-5347(17)37547-X Stoner, 1990, The clinical development of a 5α-reductase inhibitor, finasteride, J Steroid Biochem Mol Biol, 37, 375, 10.1016/0960-0760(90)90487-6 Boyarsky, 1976, A new look at bladder neck obstruction by the Food and Drug Administration regulators: guide lines for investigation of benign prostatic hypertrophy, Trans Am Assoc Genitourin Surg, 68, 29 Susset, 1983, Development of nomograms for application of uroflowmetry, 528 Levin, 1989, Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide, Urology, 34, 10, 10.1016/0090-4295(89)90147-7 Bruskewitz, 1990, Critical evaluation of trans-urethral resection and incision of the prostate, Prostate Suppl, 3, 27, 10.1002/pros.2990170504 Lepor, 1990, The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism, J Urol, 143, 533, 10.1016/S0022-5347(17)40012-7 Drach, 1979, Male peak urinary flow rate: relationship to volume voided and age, J Urol, 122, 210, 10.1016/S0022-5347(17)56333-8